Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) saw a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 172,800 shares, a growth of 315.4% from the July 15th total of 41,600 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average trading volume of 57,400 shares, the days-to-cover ratio is currently 3.0 days.

Institutional Investors Weigh In On Cyclo Therapeutics

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Founders Fund V Management LLC purchased a new stake in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics accounts for about 80.8% of Founders Fund V Management LLC’s investment portfolio, making the stock its largest holding. Founders Fund V Management LLC owned approximately 2.11% of Cyclo Therapeutics at the end of the most recent quarter. 68.55% of the stock is owned by institutional investors.

Cyclo Therapeutics Trading Down 0.8 %

Shares of NASDAQ:CYTH traded down $0.01 during mid-day trading on Tuesday, reaching $1.20. The company had a trading volume of 7,227 shares, compared to its average volume of 78,727. Cyclo Therapeutics has a one year low of $0.89 and a one year high of $2.12. The company’s 50-day moving average price is $1.21 and its 200-day moving average price is $1.40. The firm has a market cap of $34.34 million, a price-to-earnings ratio of -1.21 and a beta of -0.33.

Cyclo Therapeutics (NASDAQ:CYTH) last issued its earnings results on Wednesday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.05. Cyclo Therapeutics had a negative return on equity of 2,741.89% and a negative net margin of 1,720.76%. The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.44 million. On average, research analysts anticipate that Cyclo Therapeutics will post -0.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CYTH has been the topic of several research analyst reports. Ascendiant Capital Markets assumed coverage on Cyclo Therapeutics in a research report on Monday, April 22nd. They issued a “buy” rating and a $2.60 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of Cyclo Therapeutics in a report on Friday, May 31st.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.